STOP 301试验的其他分析表明,同时使用Trudhesa与曲坦和预防性CGRP Erenumab具有良好的耐受性,并报告了有限的治疗紧急不良事件 SEATTLE, April 26, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...